[go: up one dir, main page]

AR075249A1 - DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES. - Google Patents

DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES.

Info

Publication number
AR075249A1
AR075249A1 ARP100100317A ARP100100317A AR075249A1 AR 075249 A1 AR075249 A1 AR 075249A1 AR P100100317 A ARP100100317 A AR P100100317A AR P100100317 A ARP100100317 A AR P100100317A AR 075249 A1 AR075249 A1 AR 075249A1
Authority
AR
Argentina
Prior art keywords
radical
optionally substituted
heterocycloalkyl
phenyl
cycloalkyl
Prior art date
Application number
ARP100100317A
Other languages
Spanish (es)
Inventor
Sylvie Wentzler
Antonio Ugolini
Conception Nemecek
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR075249A1 publication Critical patent/AR075249A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Productos de formula (1) en la que - - - - representa un enlace sencillo o doble; Rb representa un átomo de hidrogeno o un átomo de fluor; Ra representa un radical -O-Z-Rc en el que Z representa un enlace sencillo o un radical alquileno lineal o ramificado que tiene de 1 a 6 átomos de carbono y que está opcionalmente sustituido con un grupo alquilo o un átomo de halogeno; Rc representa un radical cicloalquilo, heterocicloalquilo, arilo o heteroarilo opcionalmente sustituidos; X representa S, SO o SO2; A representa NH o S; W representa un átomo de hidrogeno; un radical alquilo o cicloalquilo opcionalmente sustituidos con alcoxi, heterocicloalquilo o NR3R4; o el radical COR en el que R representa un radical cicloalquilo, o un radical alquilo, opcionalmente sustituido con un radical NR3R4, alcoxi, -O-cicloalquilo, -O-CO-R5, hidroxi, fenilo, heteroarilo, o heterocicloalquilo, ellos mismos opcionalmente sustituidos; un radical alcoxi opcionalmente sustituido con NR3R4, alcoxi, hidroxi o con heterocicloalquilo; un radical O-fenilo o un radical O-(CH2)n-fenilo, con el fenilo opcionalmente sustituido y n representa un numero entero de 1 a 4; o el radical NR1R2 en el que R1 y R2 son tales que uno de R1 y R2 representa un átomo de hidrogeno, un radical cicloalquilo o un radical alquilo y el otro de R1 y R2 representa un átomo de hidrogeno, un radical cicloalquilo o un radical alquilo opcionalmente sustituido con uno o varios radicales idénticos o diferentes elegidos entre los radicales hidroxilo, alcoxi, heteroarilo, heterocicloalquilo, NR3R4, fenilo opcionalmente sustituido; o bien R1 y R2 forman con el átomo de nitrogeno al que están unidos, un radical cíclico que tiene de 3 a 10 eslabones y opcionalmente uno o varios heteroátomos distintos elegidos entre O, S, N y NH, pudiendo estar el eventual S opcionalmente en forma de SO o SO2; estando este radical, incluido el NH opcional que contiene, opcionalmente sustituido; con R3 y R4, idénticos o diferentes, representando un átomo de hidrogeno, un radical alquilo, un radical cicloalquilo, un radical heterocicloalquilo, un radical heteroarilo o un radical fenilo, todos opcionalmente sustituidos con uno o varios radicales idénticos o diferentes elegidos entre los radicales hidroxilo, alcoxi, heteroarilo, heterocicloalquilo, NH2, NHAlk, N(Alk)2, fenilo opcionalmente sustituido; o bien R3 y R4 forman con el átomo de nitrogeno al que están unidos, un radical cíclico que tiene de 3 a 10 eslabones y opcionalmente uno o varios heteroátomos distintos elegidos entre O, S, N y NH, pudiendo estar el eventual S opcionalmente en la forma de SO o SO2; estando este radical, incluido el NH opcional que contiene, opcionalmente sustituido; estando todos los radicales definidos anteriormente alquilo, alcoxi, -O-cicloalquilo, cicloalquilo, heterocicloalquilo, heteroarilo, arilo y fenilo así como los radicales cíclicos que pueden formar R1 y R2 o R3 y R4 con el átomo de nitrogeno al que están unidos, opcionalmente sustituidos con uno o varios radicales elegidos entre los átomos de halogeno, los radicales hidroxilo, oxo, alcoxi, -O-CO-R5, -OR5 -COOH, COOR5, -CONH2, CONHR5, NH2, NHR5, NR5R5', -NH-CO-R5, -NHCOOR5 y los radicales alquilo, heterocicloalquilalquilo, cicloalquilo, heterocicloalquilo, CH2- heterocicloalquilo, fenilo, CH2-fenilo, CO-fenilo, heteroarilo y S-heteroarilo, representa un arilo opcio en estos ultimos radicales, los radicales alquilo, alcoxi, heterocicloalquilo, fenilo y heteroarilo están ellos mismos opcionalmente sustituidos con uno o varios radicales elegidos entre los átomos de halogeno y los radicales hidroxilo, oxo, alquilo y alcoxi que tienen 1 a 4 átomos de carbono, NH2, NHalk y N(alk)2; estando además todos los radicales definidos anteriormente, cicloalquilo, heterocicloalquilo, heteroarilo y fenilo, opcionalmente sustituidos con un radical Si(alk)3; R5 y R5', idénticos o diferentes, representan un radical alquilo o cicloalquilo que tiene como máximo 6 átomos de carbono; alk representa un radical alquilo que tiene como máximo 4 átomos de carbono; entendiéndose que: 1) cuando Rb representa hidrogeno y Z representa un enlace sencillo, entonces Rc no representa un radical cicloalquilo; y 2) cuando Rb representa hidrogeno y Z representa un radical alquileno, entonces Rc no representa un radical heterocicloalquilo; estando dichos productos de la formula (1) en todas las formas posibles de isomeros, racémicos, enantiomeros y diastereoisomeros, así como las sales de adicion con los ácidos minerales y orgánicos o con las bases minerales y orgánicas de dichos productos de la formula (1).Claim 1: Products of formula (1) in which - - - - represents a single or double bond; Rb represents a hydrogen atom or a fluorine atom; Ra represents a radical -O-Z-Rc in which Z represents a single bond or a linear or branched alkylene radical having 1 to 6 carbon atoms and which is optionally substituted with an alkyl group or a halogen atom; Rc represents an optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical; X represents S, SO or SO2; A represents NH or S; W represents a hydrogen atom; an alkyl or cycloalkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the COR radical in which R represents a cycloalkyl radical, or an alkyl radical, optionally substituted with an NR3R4 radical, alkoxy, -O-cycloalkyl, -O-CO-R5, hydroxy, phenyl, heteroaryl, or heterocycloalkyl, themselves optionally substituted; an alkoxy radical optionally substituted with NR3R4, alkoxy, hydroxy or with heterocycloalkyl; an O-phenyl radical or an O- (CH2) n-phenyl radical, with the optionally substituted phenyl and n represents an integer from 1 to 4; or the radical NR1R2 in which R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or a radical alkyl optionally substituted with one or several identical or different radicals chosen from among the hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4, optionally substituted phenyl radicals; or R1 and R2 form with the nitrogen atom to which they are attached, a cyclic radical having 3 to 10 links and optionally one or several different heteroatoms chosen from O, S, N and NH, the eventual optionally being optionally S form of SO or SO2; this radical being, including the optional NH it contains, optionally substituted; with R3 and R4, identical or different, representing a hydrogen atom, an alkyl radical, a cycloalkyl radical, a heterocycloalkyl radical, a heteroaryl radical or a phenyl radical, all optionally substituted with one or more identical or different radicals chosen from among the radicals hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NH2, NHAlk, N (Alk) 2, optionally substituted phenyl; or R3 and R4 form with the nitrogen atom to which they are attached, a cyclic radical having 3 to 10 links and optionally one or several different heteroatoms chosen from O, S, N and NH, the eventual optionally being optionally S the form of SO or SO2; this radical being, including the optional NH it contains, optionally substituted; all the radicals defined above being alkyl, alkoxy, -O-cycloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aryl and phenyl as well as the cyclic radicals that can form R1 and R2 or R3 and R4 with the nitrogen atom to which they are optionally attached substituted with one or several radicals chosen from halogen atoms, hydroxyl, oxo, alkoxy, -O-CO-R5, -OR5 -COOH, COOR5, -CONH2, CONHR5, NH2, NHR5, NR5R5 ', -NH- CO-R5, -NHCOOR5 and the alkyl, heterocycloalkylalkyl, cycloalkyl, heterocycloalkyl, CH2-heterocycloalkyl, phenyl, CH2-phenyl, CO-phenyl, heteroaryl and S-heteroaryl radicals, represents an opium aryl in the latter radicals, the alkyl radicals, alkoxy, heterocycloalkyl, phenyl and heteroaryl are themselves optionally substituted with one or more radicals chosen from the halogen atoms and the hydroxyl, oxo, alkyl and alkoxy radicals having 1 to 4 carbon atoms, NH2, NHalk and N (alk) 2; in addition all the radicals defined above, cycloalkyl, heterocycloalkyl, heteroaryl and phenyl, optionally substituted with a Si (alk) 3 radical; R5 and R5 ', identical or different, represent an alkyl or cycloalkyl radical having a maximum of 6 carbon atoms; alk represents an alkyl radical having a maximum of 4 carbon atoms; it being understood that: 1) when Rb represents hydrogen and Z represents a single bond, then Rc does not represent a cycloalkyl radical; and 2) when Rb represents hydrogen and Z represents an alkylene radical, then Rc does not represent a heterocycloalkyl radical; said products of the formula (1) being in all possible forms of isomers, racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids or with the mineral and organic bases of said products of the formula (1 ).

ARP100100317A 2009-02-06 2010-02-05 DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES. AR075249A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0900512A FR2941950B1 (en) 2009-02-06 2009-02-06 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.

Publications (1)

Publication Number Publication Date
AR075249A1 true AR075249A1 (en) 2011-03-16

Family

ID=40872767

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100317A AR075249A1 (en) 2009-02-06 2010-02-05 DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES.

Country Status (19)

Country Link
EP (1) EP2393791A1 (en)
JP (1) JP2012517408A (en)
KR (1) KR20110132560A (en)
CN (1) CN102378759A (en)
AR (1) AR075249A1 (en)
AU (1) AU2010212232A1 (en)
BR (1) BRPI1008232A2 (en)
CA (1) CA2750875A1 (en)
CL (1) CL2011001879A1 (en)
CO (1) CO6400223A2 (en)
EA (1) EA201171011A1 (en)
FR (1) FR2941950B1 (en)
IL (1) IL214406A0 (en)
MA (1) MA33107B1 (en)
MX (1) MX2011008319A (en)
SG (1) SG173559A1 (en)
TW (1) TW201031670A (en)
UY (1) UY32420A (en)
WO (1) WO2010089507A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
BR112014006924B1 (en) * 2011-09-27 2020-10-06 Genfit 6-REPLACED TRIAZOLOPYRIDAZINES DERIVATIVES AS REV-ERB AGONISTS
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR20250164828A (en) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Composition for inducing RAS GTP hydrolysis and use thereof
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
RS55630B1 (en) * 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv TRIAZOLOPYRIDASINES AS TYROSINE KINASE MODULATORS
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (en) * 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
MX2009004059A (en) * 2006-10-23 2009-04-27 Sgx Pharmaceuticals Inc Bicyclic triazoles as protein kinase modulators.
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
TW201031670A (en) 2010-09-01
CO6400223A2 (en) 2012-03-15
AU2010212232A1 (en) 2011-08-25
FR2941950A1 (en) 2010-08-13
CN102378759A (en) 2012-03-14
KR20110132560A (en) 2011-12-08
IL214406A0 (en) 2011-09-27
MX2011008319A (en) 2012-01-25
MA33107B1 (en) 2012-03-01
FR2941950B1 (en) 2011-04-01
UY32420A (en) 2010-09-30
SG173559A1 (en) 2011-09-29
EP2393791A1 (en) 2011-12-14
WO2010089507A1 (en) 2010-08-12
BRPI1008232A2 (en) 2016-03-08
EA201171011A1 (en) 2012-03-30
CA2750875A1 (en) 2010-08-12
CL2011001879A1 (en) 2012-01-06
JP2012517408A (en) 2012-08-02

Similar Documents

Publication Publication Date Title
AR075249A1 (en) DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLES, METHOD OF PREPARATION OF THE SAME AND INTERMEDIARIES OF SUCH SYNTHESIS, MEDICINES CONTAINING THEM AND USE OF THE MYSTS AND ALERTS IN THE TRACKS, ALERTS OTHER DISEASES.
AR068055A1 (en) DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL ITS PREPARATION PROCEDURE ITS APPLICATION AS MEDICINES PHARMACEUTICAL COMPOSITIONS AND ITS MAIN USE AS MET INHIBITORS
CO6700838A2 (en) Banzamide Substituted Compounds
AR091498A1 (en) DERIVATIVES OF 2,3-DIHIDRO-1H-IMIDAZO {1,2-a} PIRIMIDIN-5-ONA AND 1,2,3,4-TETRAHYDRO-PYRIMID {1,2-a} PYRIMIDIN-6-ONA CONTAINING A SUBSTITUTED MORPHOLINE, ITS PREPARATION AND ITS PHARMACEUTICAL USE
AR093515A1 (en) TRIAZOLOPIRAZINS
CO6430424A2 (en) SUBSTITUTED COMPOUNDS OF ESPIRO-AMIDA
AR096979A1 (en) DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DOP2013000046A (en) PEST CONTROL AGENT
AR095426A1 (en) TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
DOP2013000088A (en) REINFORCEMENT BAR AND METHOD FOR MANUFACTURING THE SAME
AR059085A1 (en) SUCCESSFUL DERIVATIVES OF UREA CYCLES ITS PREPARATION AND ITS PHARMACEUTICAL USE AS INHIBITORS OF KINASES
CR10643A (en) DERIVATIVES OF 2-ARIL-6-FENIL-IMIDAZOL [1,2-a] PIRIDINAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
AR068912A1 (en) DERIVATIVES OF 6- ARIL / HETEROARILQUILOXI BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND USE AS CMET INHIBITORS
AR072819A1 (en) DERIVATIVES OF TRIAZOLO [4,3-A] PIRIDINE, PREPARATION PROCEDURE, INTERMEDIARIES OF SUCH PROCESS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THE SAME, AS INHIBITORS OF MET PROTEINQUINASE, FOR THE TREATMENT OF CANCERESIST, PSCESESIS, PSC CENTRAL NERVOUS AND OTHER
AR059086A1 (en) DERIVED FROM UREA CYCLES ITS PREPARATION AND ITS PHARMACEUTICAL USE AS INHIBITORS OF KINASES
AR072518A1 (en) IMIDAZO DERIVATIVES [1,2-A] PIRIDINE, ITS PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS AND ITS PARTICULAR USE AS MET INHIBITORS. "
AR086590A1 (en) CYCLHEXANONE AND HERBICIDE COMPOUNDS THAT UNDERSTAND THEM
AR094852A1 (en) OESTRA-1,3,5 (10), 16-TETRAENE-3-CARBOXAMIDS
CO6341610A2 (en) AROMATIC HETEROCICLYL COMPOUND CONTAINING NITROGEN.
AR077510A1 (en) DERIVATIVES OF DIHYDROINDOLONES, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COM-POSITIONS CONTAINING THEM
AR087487A1 (en) HETEROCICLIC COMPOUNDS DERIVED FROM PYRIMIDINE AS INHIBITORS OF THE JANUS ACTIVATED KINASES (JAK)
AR075251A1 (en) DERIVATIVES OF 6- (6-REPLACED-TRIAZOLOPIRIDAZINA-SULFANIL) -5-FLUORO-BENZOTIAZOLES AND 5-FLUORO-BENCIMIDAZOLS, METHOD OF PREPARATION AND INTERMEDIARIES OF SYNTHESIS, PHARMACEUTICAL COMPOSITIONS FOR THE CONTAINMENT AND USE OF THE CANTATION AND USE OTHER HYPERPROLIFERATIVE DISORDERS.
AR074916A1 (en) DERIVATIVES OF 2-PIRIDIN-2-IL-PIRAZOL-3 (2H) -ONA, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN CARDIOVASCULAR DISEASES.
CR9499A (en) NEW DERIVATIVES OF PHENYLPIRIDINYLPIPERAZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR075250A1 (en) DERIVATIVES OF 6- (TRIAZOLOPIRIDAZINSULFANIL REPLACED IN 6-NH) BENZOTIAZOLES AND BENCIMIDAZOLES; PREPARATION, APPLICATION AS MEDICINES AND USE AS INHIBITORS OF MET.

Legal Events

Date Code Title Description
FB Suspension of granting procedure